{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:53:05Z","timestamp":1793040785195,"version":"4.5.0"},"publisher-location":"Cham","reference-count":80,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319914411","type":"print"},{"value":"9783319914428","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-3-319-91442-8_8","type":"book-chapter","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T20:13:35Z","timestamp":1533154415000},"page":"101-123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Everolimus"],"prefix":"10.1007","author":[{"given":"Jens","family":"Hasskarl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"issue":"34","key":"8_CR1","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1200\/JCO.2009.27.8549","volume":"28","author":"F Andre","year":"2010","unstructured":"Andre F et al (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol: Official J Am Soc Clin Oncol 28(34):5110\u20135115","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"issue":"6","key":"8_CR2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","volume":"15","author":"F Andre","year":"2014","unstructured":"Andre F et al (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15(6):580\u2013591","journal-title":"Lancet Oncol"},{"issue":"1","key":"8_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejca.2007.10.003","volume":"44","author":"A Awada","year":"2008","unstructured":"Awada A et al (2008) The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 44(1):84\u201391","journal-title":"Eur J Cancer"},{"issue":"4","key":"8_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3324\/haematol.2012.075184","volume":"98","author":"JA Barnes","year":"2013","unstructured":"Barnes JA et al (2013) Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica 98(4):615\u2013619","journal-title":"Haematologica"},{"issue":"16","key":"8_CR5","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","volume":"27","author":"J Baselga","year":"2009","unstructured":"Baselga J et al (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol: Official J Am Soc Clin Oncol 27(16):2630\u20132637","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"issue":"6","key":"8_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J et al (2012a) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520\u2013529","journal-title":"N Engl J Med"},{"issue":"2","key":"8_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J et al (2012b) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New England J Med 366(2):109\u2013119","journal-title":"New England J Med"},{"issue":"9869","key":"8_CR8","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381(9869):817\u2013824","journal-title":"Lancet"},{"issue":"5","key":"8_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","volume":"4","author":"MA Bjornsti","year":"2004","unstructured":"Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4(5):335\u2013348","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"8_CR10","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1158\/1078-0432.CCR-04-2402","volume":"11","author":"A Boulay","year":"2005","unstructured":"Boulay A et al (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res: Official J Am Assoc Cancer Res 11(14):5319\u20135328","journal-title":"Clin Cancer Res: Official J Am Assoc Cancer Res"},{"issue":"9","key":"8_CR11","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A et al (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3\u00a0K-dependent feedback loop in human cancer. J Clin Investig 118(9):3065\u20133074","journal-title":"J Clin Investig"},{"issue":"8","key":"8_CR12","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/sj.bjc.6602162","volume":"91","author":"S Chan","year":"2004","unstructured":"Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91(8):1420\u20131424","journal-title":"Br J Cancer"},{"issue":"14","key":"8_CR13","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1182\/blood-2008-02-137752","volume":"113","author":"R Crazzolara","year":"2009","unstructured":"Crazzolara R et al (2009) Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 113(14):3297\u20133306","journal-title":"Blood"},{"issue":"11","key":"8_CR14","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1200\/JCO.2009.26.2923","volume":"28","author":"T Doi","year":"2010","unstructured":"Doi T et al (2010) Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol: Official J Am Soc Clin Oncol 28(11):1904\u20131910","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"issue":"8","key":"8_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1788","volume":"14","author":"D Ehninger","year":"2008","unstructured":"Ehninger D et al (2008) Reversal of learning deficits in a Tsc2\u00b1 mouse model of tuberous sclerosis. Nat Med 14(8):843\u2013848","journal-title":"Nat Med"},{"issue":"1 Pt 1","key":"8_CR16","first-page":"868","volume":"23","author":"CP Eng","year":"1991","unstructured":"Eng CP et al (1991) Inhibition of skin graft rejection in mice by rapamycin: a novel immunosuppressive macrolide. Transplant Proc 23(1 Pt 1):868\u2013869","journal-title":"Transplant Proc"},{"issue":"8","key":"8_CR17","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1586\/era.11.93","volume":"11","author":"DN Franz","year":"2011","unstructured":"Franz DN (2011) Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert Rev Anticancer Ther 11(8):1181\u20131192","journal-title":"Expert Rev Anticancer Ther"},{"key":"8_CR18","first-page":"211","volume":"7","author":"DN Franz","year":"2013","unstructured":"Franz DN (2013) Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics 7:211\u2013221","journal-title":"Biologics"},{"issue":"6","key":"8_CR19","doi-asserted-by":"publisher","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","volume":"11","author":"DN Franz","year":"2016","unstructured":"Franz DN et al (2016) Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS ONE 11(6):e0158476","journal-title":"PLoS ONE"},{"issue":"10056","key":"8_CR20","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA et al (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388(10056):2153\u20132163","journal-title":"Lancet"},{"issue":"4","key":"8_CR21","first-page":"1527","volume":"61","author":"B Geoerger","year":"2001","unstructured":"Geoerger B et al (2001) Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor\/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61(4):1527\u20131532","journal-title":"Cancer Res"},{"issue":"13","key":"8_CR22","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1200\/JCO.2009.26.3152","volume":"28","author":"JD Hainsworth","year":"2010","unstructured":"Hainsworth JD et al (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol: Official J Am Soc Clin Oncol 28(13):2131\u20132136","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"issue":"2","key":"8_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/sj.leu.2404471","volume":"21","author":"T Haritunians","year":"2007","unstructured":"Haritunians T et al (2007) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21(2):333\u2013339","journal-title":"Leukemia"},{"issue":"5","key":"8_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2014.60.1971","volume":"34","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN et al (2016) Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol 34(5):419\u2013426","journal-title":"J Clin Oncol"},{"issue":"5","key":"8_CR25","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-09-1314","volume":"16","author":"PJ Houghton","year":"2010","unstructured":"Houghton PJ (2010) Everolimus. Clin Cancer Res 16(5):1368\u20131372","journal-title":"Clin Cancer Res"},{"issue":"3","key":"8_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10549-013-2689-5","volume":"141","author":"SA Hurvitz","year":"2013","unstructured":"Hurvitz SA et al (2013) A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat 141(3):437\u2013446","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"8_CR27","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/j.1582-4934.2008.00364.x","volume":"13","author":"H Huynh","year":"2009","unstructured":"Huynh H et al (2009) RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 13(7):1371\u20131380","journal-title":"J Cell Mol Med"},{"issue":"11","key":"8_CR28","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/ncb1183","volume":"6","author":"E Jacinto","year":"2004","unstructured":"Jacinto E et al (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6(11):1122\u20131128","journal-title":"Nat Cell Biol"},{"issue":"2","key":"8_CR29","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10549-010-1260-x","volume":"125","author":"G Jerusalem","year":"2011","unstructured":"Jerusalem G et al (2011) Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 125(2):447\u2013455","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"8_CR30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","volume":"85","author":"PB Johnston","year":"2010","unstructured":"Johnston PB et al (2010) A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 85(5):320\u2013324","journal-title":"Am J Hematol"},{"issue":"6","key":"8_CR31","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/annonc\/mdx075","volume":"28","author":"JJ Knox","year":"2017","unstructured":"Knox JJ et al (2017) Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol 28(6):1339\u20131345","journal-title":"Ann Oncol"},{"issue":"19","key":"8_CR32","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger DA et al (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. New England J Med 363(19):1801\u20131811","journal-title":"New England J Med"},{"issue":"5","key":"8_CR33","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-08-2057","volume":"15","author":"HA Lane","year":"2009","unstructured":"Lane HA et al (2009) mTOR inhibitor RAD001 (everolimus) has antiangiogenic\/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res: Official J Am Assoc Cancer Res 15(5):1612\u20131622","journal-title":"Clin Cancer Res: Official J Am Assoc Cancer Res"},{"issue":"2","key":"8_CR34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274\u2013293","journal-title":"Cell"},{"issue":"3","key":"8_CR35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1101\/gad.1363206","volume":"20","author":"AJ Levine","year":"2006","unstructured":"Levine AJ et al (2006) Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 20(3):267\u2013275","journal-title":"Genes Dev"},{"issue":"19","key":"8_CR36","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-06-2837","volume":"13","author":"CH Lu","year":"2007","unstructured":"Lu CH et al (2007) Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res: Official J Am Assoc Cancer Res 13(19):5883\u20135888","journal-title":"Clin Cancer Res: Official J Am Assoc Cancer Res"},{"issue":"6","key":"8_CR37","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nm1052","volume":"10","author":"PK Majumder","year":"2004","unstructured":"Majumder PK et al (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10(6):594\u2013601","journal-title":"Nat Med"},{"issue":"4","key":"8_CR38","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1081\/CNV-200027144","volume":"22","author":"BC Mak","year":"2004","unstructured":"Mak BC, Yeung RS (2004) The tuberous sclerosis complex genes in tumor development. Cancer Invest 22(4):588\u2013603","journal-title":"Cancer Invest"},{"issue":"Pt 3","key":"8_CR39","first-page":"573","volume":"31","author":"BD Manning","year":"2003","unstructured":"Manning BD, Cantley LC (2003) United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase\/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans 31(Pt 3):573\u2013578","journal-title":"Biochem Soc Trans"},{"issue":"21","key":"8_CR40","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","volume":"28","author":"L Meikle","year":"2008","unstructured":"Meikle L et al (2008) Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci: Official J Soc Neurosci 28(21):5422\u20135432","journal-title":"J Neurosci: Official J Soc Neurosci"},{"issue":"12","key":"8_CR41","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1517\/13543780802556485","volume":"17","author":"M Mita","year":"2008","unstructured":"Mita M et al (2008) Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs 17(12):1947\u20131954","journal-title":"Expert Opin Investig Drugs"},{"issue":"9637","key":"8_CR42","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449\u2013456","journal-title":"Lancet"},{"issue":"18","key":"8_CR43","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256\u20134265","journal-title":"Cancer"},{"issue":"3","key":"8_CR44","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/annonc\/mdv612","volume":"27","author":"RJ Motzer","year":"2016","unstructured":"Motzer RJ et al (2016) Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). Ann Oncol 27(3):441\u2013448","journal-title":"Ann Oncol"},{"issue":"2","key":"8_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","volume":"6","author":"Y Nagata","year":"2004","unstructured":"Nagata Y et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117\u2013127","journal-title":"Cancer Cell"},{"issue":"1","key":"8_CR46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3892\/or.2016.5232","volume":"37","author":"Y Nakai","year":"2017","unstructured":"Nakai Y et al (2017) Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus. Oncol Rep 37(1):227\u2013234","journal-title":"Oncol Rep"},{"issue":"12","key":"8_CR47","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1038\/leu.2008.243","volume":"22","author":"C Nishioka","year":"2008","unstructured":"Nishioka C et al (2008) Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 22(12):2159\u20132168","journal-title":"Leukemia"},{"issue":"10","key":"8_CR48","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","volume":"26","author":"A O\u2019Donnell","year":"2008","unstructured":"O\u2019Donnell A et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol: Official J Am Soc Clin Oncol 26(10):1588\u20131595","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"issue":"2","key":"8_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1593\/tlo.09277","volume":"3","author":"T O\u2019Reilly","year":"2010","unstructured":"O\u2019Reilly T, McSheehy PM (2010) Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 3(2):65\u201379","journal-title":"Transl Oncol"},{"issue":"4","key":"8_CR50","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00280-009-1068-8","volume":"65","author":"T O\u2019Reilly","year":"2010","unstructured":"O\u2019Reilly T et al (2010) Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol 65(4):625\u2013639","journal-title":"Cancer Chemother Pharmacol"},{"issue":"31","key":"8_CR51","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","volume":"31","author":"A Ohtsu","year":"2013","unstructured":"Ohtsu A et al (2013) Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 31(31):3935\u20133943","journal-title":"J Clin Oncol"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1749-6632.2009.05117.x","volume":"1184","author":"KA Orlova","year":"2010","unstructured":"Orlova KA, Crino PB (2010) The tuberous sclerosis complex. Ann N Y Acad Sci 1184:87\u2013105","journal-title":"Ann N Y Acad Sci"},{"issue":"9808","key":"8_CR53","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel ME et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005\u20132012","journal-title":"Lancet"},{"issue":"7","key":"8_CR54","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/annonc\/mdx193","volume":"28","author":"ME Pavel","year":"2017","unstructured":"Pavel ME et al (2017a) Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol 28(7):1569\u20131575","journal-title":"Ann Oncol"},{"issue":"4","key":"8_CR55","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/cpt.559","volume":"101","author":"ME Pavel","year":"2017","unstructured":"Pavel ME et al (2017b) Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial. Clin Pharmacol Ther 101(4):462\u2013468","journal-title":"Clin Pharmacol Ther"},{"issue":"18","key":"8_CR56","doi-asserted-by":"publisher","first-page":"10320","DOI":"10.1073\/pnas.171060098","volume":"98","author":"K Podsypanina","year":"2001","unstructured":"Podsypanina K et al (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten\u00b1 mice. Proc Natl Acad Sci USA 98(18):10320\u201310325","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"8_CR57","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1093\/annonc\/mdv170","volume":"26","author":"A Ravaud","year":"2015","unstructured":"Ravaud A et al (2015) RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon alpha-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 26(7):1378\u20131384","journal-title":"Ann Oncol"},{"issue":"7","key":"8_CR58","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","volume":"97","author":"C Renner","year":"2012","unstructured":"Renner C et al (2012) A multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 97(7):1085\u20131091","journal-title":"Haematologica"},{"issue":"1","key":"8_CR59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3324\/haematol.2010.026997","volume":"96","author":"P Saunders","year":"2011","unstructured":"Saunders P et al (2011) The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica 96(1):69\u201377","journal-title":"Haematologica"},{"issue":"1","key":"8_CR60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","volume":"64","author":"W Schuler","year":"1997","unstructured":"Schuler W et al (1997) SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64(1):36\u201342","journal-title":"Transplantation"},{"issue":"6","key":"8_CR61","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/00007691-199512000-00019","volume":"17","author":"SN Sehgal","year":"1995","unstructured":"Sehgal SN (1995) Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 17(6):660\u2013665","journal-title":"Ther Drug Monit"},{"issue":"2","key":"8_CR62","doi-asserted-by":"publisher","first-page":"R32","DOI":"10.1186\/bcr3634","volume":"16","author":"J Singh","year":"2014","unstructured":"Singh J et al (2014) Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res 16(2):R32","journal-title":"Breast Cancer Res"},{"issue":"6","key":"8_CR63","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","volume":"14","author":"SM Swain","year":"2013","unstructured":"Swain SM et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461\u2013471","journal-title":"Lancet Oncol"},{"issue":"6","key":"8_CR64","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1007\/s10637-010-9464-9","volume":"29","author":"F Taguchi","year":"2011","unstructured":"Taguchi F et al (2011) Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest New Drugs 29(6):1198\u20131205","journal-title":"Invest New Drugs"},{"issue":"19","key":"8_CR65","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. New England J Med 367(19):1783\u20131791","journal-title":"New England J Med"},{"key":"8_CR66","doi-asserted-by":"crossref","unstructured":"Villanueva A et al (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology, 2008. 135(6):1972\u201383, 1983 e1\u201311","DOI":"10.1053\/j.gastro.2008.08.008"},{"issue":"4","key":"8_CR67","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/bjh.12780","volume":"165","author":"M Wang","year":"2014","unstructured":"Wang M et al (2014) Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol 165(4):510\u2013518","journal-title":"Br J Haematol"},{"issue":"5","key":"8_CR68","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2141.2006.06210.x","volume":"134","author":"K Wanner","year":"2006","unstructured":"Wanner K et al (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134(5):475\u2013484","journal-title":"Br J Haematol"},{"key":"8_CR69","doi-asserted-by":"crossref","unstructured":"Witzig TE et al (2016) PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 34(15_suppl):7506\u20137506","DOI":"10.1200\/JCO.2016.34.15_suppl.7506"},{"issue":"2","key":"8_CR70","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/leu.2010.226","volume":"25","author":"TE Witzig","year":"2011","unstructured":"Witzig TE et al (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25(2):341\u2013347","journal-title":"Leukemia"},{"issue":"5","key":"8_CR71","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2217\/fnl.12.45","volume":"7","author":"M Wong","year":"2012","unstructured":"Wong M (2012) mTOR as a potential treatment target for epilepsy. Future Neurol 7(5):537\u2013545","journal-title":"Future Neurol"},{"key":"8_CR72","doi-asserted-by":"crossref","unstructured":"Xu ZZ et al (2013) Combination of Rituximab and the mTOR inhibitor Everolimus (RAD001) in Diffuse large B cell lymphoma. Leuk Lymphoma","DOI":"10.3109\/10428194.2013.823492"},{"key":"8_CR73","doi-asserted-by":"crossref","unstructured":"Yao JC et al (2016) Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol","DOI":"10.1200\/JCO.2016.68.0702"},{"issue":"26","key":"8_CR74","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC et al (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol: Official J Am Soc Clin Oncol 26(26):4311\u20134318","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"issue":"1","key":"8_CR75","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","volume":"28","author":"JC Yao","year":"2010","unstructured":"Yao JC et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol: Official J Am Soc Clin Oncol 28(1):69\u201376","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"issue":"6","key":"8_CR76","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. New England J Med 364(6):514\u2013523","journal-title":"New England J Med"},{"issue":"10022","key":"8_CR77","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387(10022):968\u2013977","journal-title":"Lancet"},{"issue":"6","key":"8_CR78","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/bjc.2012.47","volume":"106","author":"DH Yoon","year":"2012","unstructured":"Yoon DH et al (2012) Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 106(6):1039\u20131044","journal-title":"Br J Cancer"},{"issue":"122","key":"8_CR79","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1002\/cncr.26165","volume":"117","author":"AX Zhu","year":"2011","unstructured":"Zhu AX et al (2011) Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 117(122):5094\u20135102","journal-title":"Cancer"},{"issue":"1","key":"8_CR80","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2014.7189","volume":"312","author":"AX Zhu","year":"2014","unstructured":"Zhu AX et al (2014) Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312(1):57\u201367","journal-title":"JAMA"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-91442-8_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T21:46:54Z","timestamp":1720475214000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-91442-8_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783319914411","9783319914428"],"references-count":80,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-91442-8_8","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}